and Human Services
9000 Rockville Pike
Bethesda, Maryland 20892
THE EARLY DETECTION RESEARCH NETWORK: BIOMARKER DEVELOPMENTAL LABORATORIES
RELEASE DATE: August 27, 2004
RFA Number: RFA-CA-05-023
Update: The following update relating to this announcement has been issued:
June 26, 2009 - This RFA has been reissued as (RFA-CA-09-017).
EXPIRATION DATE: December 21, 2004
Department of Health and Human Services (DHHS)
PARTICIPATING ORGANIZATION:
National Institutes of Health (NIH)
(http://www.nih.gov)
COMPONENT OF PARTICIPATING ORGANIZATION:
National Cancer Institute (NCI)
(http://www.nci.nih.gov/)
CATALOG OF FEDERAL DOMESTIC ASSISTANCE NUMBER(S): 93.394
LETTER OF INTENT RECEIPT DATE: November 22, 2004
APPLICATION RECEIPT DATE: December 20, 2004
This RFA is a reissue of RFA CA-04-006, which was published in the NIH Guide on
September 22, 2003.
THIS RFA CONTAINS THE FOLLOWING INFORMATION
o Purpose of this RFA
o Research Objectives
o Mechanism of Support
o Funds Available
o Eligible Institutions
o Individuals Eligible to Become Principal Investigators
o Special Requirements
o Where to Send Inquiries
o Letter of Intent
o Submitting an Application
o Supplementary Instructions
o Peer Review Process
o Review Criteria
o Receipt and Review Schedule
o Award Criteria
o Required Federal Citations
PURPOSE OF THIS RFA
The Division of Cancer Prevention (DCP), National Cancer Institute (NCI),
invites new and competing renewal cooperative agreement and NIH intramural
applications to continue the national Network that has the responsibility for
the development, evaluation, and validation of biomarkers for earlier cancer
detection and risk assessment. Biomarkers are defined as cellular, biochemical,
and molecular (including genetic and epigenetic) alterations by which a normal,
abnormal, or simply biologic process can be recognized or monitored. Biomarkers
are measurable in biological media, such as in tissues, cells, or fluids. The
Network has four main components – Biomarker Developmental Laboratories (BDL),
Biomarker Reference Laboratories (formerly known as Biomarker Validation
Laboratories), Clinical Epidemiology and Validation Centers (formerly known as
Clinical and Epidemiologic Centers), and a Data Management and Coordinating
Center (DMCC). The Biomarker Developmental Laboratories have responsibility for
the development and characterization of new, or the refinement of existing,
biomarkers and assays. The Biomarker Reference Laboratories serve as a Network
resource for clinical and laboratory validation of biomarkers, including
technological development and refinement. The Clinical Epidemiology and
Validation Centers collaboratively conduct clinical and epidemiological
research on the Network-wide clinical validation of biomarkers. The Data
Management and Coordinating Center supports statistical and computational
analysis, informatics infrastructure, and coordinates network-wide meetings and
conferences. For further details, see http://www.cancer.gov/edrn.
The EDRN Steering Committee (SC) is composed of the Principal Investigators
(PIs) in the Network and appropriate NCI staff to coordinate the work of the
Network.
The purpose of this reissuance is to invite new and competing renewal
applications to add additional Biomarker Development Laboratories and to ensure
biomarker studies on all cancers of common occurrence are supported. Special
emphasis should be placed on cancers of common occurrence, with high priority
given to studies of breast, lung, ovarian, colon, pancreatic, and prostate and
other less prevalent epithelial cancers, which are the major causes of cancer-
related mortality and have yet to be controlled with screening and prevention.
Separate RFAs had already been issued to establish the Biomarker Reference
Laboratories, Clinical Epidemiology and Validation Centers, and the Data
Management and Coordinating Center. Applicants are encouraged to participate
in more than one component, because it is recognized that collaboration already
exists in individual institutions for clinical testing and validation of
biomarkers/reagents.
RESEARCH OBJECTIVES
A. Background
The Network has a straightforward mission: to translate newly emerging
molecular knowledge into practical clinical tests to detect cancer and cancer
risk. For most cancers, successful treatment depends on early detection and
successful prevention depends on the accurate evaluation of risk. The Early
Detection Research Network (EDRN) seeks to give treatments the opportunity to
work and to make prevention possible.
The Network is using cutting-edge technologies to identify the changes that
occur in the earliest stages of transformation of a normal cell into a
cancerous cell. Scientific expertise from leading national and international
institutions has been harnessed to first identify, and then validate, crucial
molecular markers to detect cancer and to assess cancer risk. The Network is
an investigator-initiated Network for collaborative research created to link
the discovery of biologic markers directly to the next steps in the process of
developing early detection tests. The power of bioinformatics and computer-
assisted programs is being put to full use to analyze Network data and to
produce answers to key questions more quickly. The use of new technologies,
such as genomics, epigenomics, and proteomics allows the identification of
genetic as well as antigenic changes during the early stages of malignant
progression. Some of these changes show promise as biomarkers of preneoplastic
development or of early malignant transformation. The application of these
emerging technologies in the field of early detection and risk assessment is a
high priority in the NCI’s strategy for reducing mortality from cancer. Early
detection of cancer has been identified as an area of extraordinary opportunity
for research investment in the NCI 2004 Bypass Budget
(http://plan.cancer.gov/).
The Network is an opportunity and a challenge for the scientific community – an
opportunity to make science work for people and a challenge to make this new
model of collaboration a productive scientific construct. Collaborations and
partnerships that are necessary for our ultimate success of this project have
been put into place. The acceleration of scientific progress through the
Network is faster than it has ever been; consequently, the need for clinical
application is now greater than ever. Early detection technologies are also
rapidly evolving while existing technologies are undergoing progressive
refinement in their sensitivity, specificity, and high-throughput. Improved
analytic tools have allowed a more detailed examination of the molecular basis
of carcinogenesis and have provided the ability to identify the molecular and
cellular signatures of cancer and to explore the gene-environment interactions
relevant to early detection. To explore fully the application of molecular
profiles for earlier detection and risk assessment, it is essential to
understand the molecular pathogenesis of cancer, that is, the natural history
of tumor progression at the molecular level, so that the biological behavior of
an evolving lesion (i.e., dysplasia or field change) can be predicted with
greater accuracy. Current observations indicate that cancers usually evolve
through many complex cellular processes, pathways, and networks. A better
understanding of the circuits in these pathways is critical if we are to
successfully apply these molecular-based technologies to earlier detection.
Since its inception in 1999, the EDRN has followed a “vertical” approach to
biomarker research — that is, an established, integrated, multidisciplinary
environment that would facilitate collaboration among technology developers,
basic scientists, clinicians, epidemiologists, biostatisticians, and other
health professionals, and therefore would expedite efficacious clinical
applications of the molecular knowledge that has burgeoned in recent years
(Srivastava, 1999). The Network has produced a system for evaluating biomarkers
as tools to clinically detect cancer before symptoms appear, and to identify
people at risk (http://www.cancer.gov/edrn). A five-phase approach has been
established as a standard and a road map for successfully translating research
on biomarker applications from the laboratory to the bedside (Pepe, M.S.,
Etzioni, R., Feng, Z., Potter, J., et. al.,[2001]. Phases of biomarker
development for early detection of cancer. J Natl Cancer Inst. 93, 1054-1061).
These phases are:
Phase I: exploratory studies to identify potentially useful biomarkers – (i.e.,
the “discovery” phase);
Phase II: biomarkers are studied to determine their capacity for distinguishing
between people with cancer and those without – (i.e., the “validation” phase);
Phase III: studies to assess the capacity of a biomarker to detect preclinical
disease by testing the marker against tissues collected longitudinally from
research cohorts;
Phase IV: prospective screening studies; and
Phase V: definitive large-scale population studies to determine the overall
impact of screening on health outcomes in the target population.
Significant progress has been made by the EDRN investigators from discovery to
development, to validation, and to application. The pace at which molecular
signatures, (e.g., proteomics, genomics) associated with causal pathways and
processes are identified is accelerating. However, major challenges remain in
integrating these discoveries and developments into clinical practice. The
Network stimulates collaborative research to meet this challenge by supporting
translational research. For further research activities across the Network, see
http://www.cancer.gov/edrn. Applicants are encouraged to see the EDRN second
progress report at
http://www3.cancer.gov/prevention/cbrg/edrn/edrn_report2002.pdf.
Applicants are strongly encouraged to forge partnerships with industry,
including biotechnology firms, to develop biomarkers, reagents, technologies,
and assays. The Network continues to serve as an attractive source of
collaborations for industry, since it will provide clinical opportunities for
the evaluation of new technologies. The Network will encourage collaborations
with industry in order to leverage funds awarded under this RFA. NCI funds will
be used to support the underlying infrastructure and the cost of studies not
having direct implications for a company’s product development or marketing
strategy. NCI views partnerships with industry as an important component of the
EDRN mission. However, with respect to new technologies and/or reagents
provided by such participants that are part of development or product plans,
the individual companies will be responsible for costs in such areas as
technology standardization and quality assurance as well as scale-up of
laboratory techniques, collection and formatting of specialized data required
by regulatory agencies for device approvals, preparation of registration
documents, and supporting a portion of the accrual to studies pivotal for
registration.
B. Network Administrative Structures
Network Organization: Structured around four main components, the Network
currently includes 18 Biomarker Developmental Laboratories (BDLs), three
Biomarker Reference Laboratories (BRLs), nine Clinical and Epidemiologic
Validation Centers (CEVCs), and a Data Management and Coordinating Center
(DMCC)(The Early Detection Research Network: Translational Research to Identify
Early Cancer Risk; NCI Publication No. 01-4852, August 2001).
o The Biomarker Developmental Laboratories develop and characterize new
biomarkers, or refine existing biomarkers (Phase I and Phase II). (See
previous BDL RFA at
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-04-006.html.)
o The Biomarker Reference Laboratories serve as a resource for the clinical
and analytical validation of biomarkers, including development of technology,
standardization of assay methods, and refinement of existing methods. (See
previous BRL RFA at
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-05-009.html.)
o The Clinical Epidemiology and Validation Centers conduct early phases
(Phase II and Phase III) of clinical validation and epidemiological research
into the application of biomarkers. (See previous CECV RFA at
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-05-005.html.)
The Data Management and Coordinating Center provides statistical, logistics,
and informatics support and develops the theoretical and statistical approaches
to the simultaneous pattern analysis of multiple markers. (See previous RFA
DMCC at http://grants.nih.gov/grants/guide/rfa-files/rfa-ca-99-011.html.)
Four federal agencies participate in the EDRN through interagency agreements:
the National Institute of Standards and Technology (NIST), which serves as a
validation laboratory; the Centers for Disease Control and Prevention (CDC)
which serves as a Clinical and Epidemiologic Center; the Food and Drug
Administration (FDA); and the Jet Propulsion Laboratory (JPL), National
Aeronautics and Space Administration (NASA), which provides informatics
support.
Each component is funded through a separate RFA. An applicant, however, may
seek funding to participate in more than one component. Each awardee will
conduct independent research using their U01 funds and collaborative research
using the Core Funds from the Headquarters (see definition of a Headquarters
below) and from the set-aside funds in their U01 pending approval by the
Steering Committee and release by the NCI, respectively.
Each laboratory/center will be managed by a PI and may include academic and
industrial biotechnology investigators who are involved in cancer detection and
diagnostic research. In order to expedite the translational research, the
Network will be supplemented by the ad hoc participation of additional
investigators (academic or community-based) who are able to validate the
results of laboratory studies through patient accrual.
Currently, the Network consists of experts in basic molecular science,
laboratory technology, clinical studies, biometry, and epidemiology. The
expertise in laboratory science includes conducting research on the biology of
incipient neoplasia encompassing the development, characterization, and testing
of biomarkers of early cancer and risk and developing of relevant technologies
for biomarker detection, and analytical tools for the evaluation of biomarkers
for detection, and risk assessment. The expertise in laboratory validation
includes knowledge and practice of Standard Operating Procedures (SOPs), and
experience in the statistical evaluation of accuracy, precision,
reproducibility, and performance characteristics of tests in multi-center
settings. Expertise in patient accrual and associated clinical issues for
studies will be needed to apply basic science discoveries to clinical settings.
Computational and informatic needs of the Network are provided by a Data
Management and Coordinating Center and the JPL.
Steering Committee: The Steering Committee (SC) has responsibility for
scientific management and oversight, including monitoring the activities of the
DMCC. For administrative structure, and responsibilities of the Steering
Committee, see “Collaborative Responsibilities.”
Network Consulting Committee (NCC): A separate advisory committee has been
established by the NCI to ensure that the overall Network is adequately
responsive to promising opportunities, exhibits the desired degree of
flexibility in composition and decision-making, and makes prioritization
decisions free from conflicts of interest. For further details, see
“Collaborative Responsibilities.”
Data Management and Coordinating Center (DMCC): The Data Management and
Coordinating Center provides logistic support for the conduct of the SC and NCC
meetings, provides statistical and data management support for protocol
development, conducts analyses of clinical data, and develops informatics
(i.e., information technologies). It studies applied and theoretical approaches
to the simultaneous analysis of multiple markers. In addition, the DMCC, in
collaboration with JPL and EDRN investigators, has developed common
informatics, Common Data Elements (CDEs) and analytical tools for the
interpretation of data, and instruments for checking uniformity, consistency,
accuracy, timeliness, reproducibility, and privacy of the data.
Headquarters: The institution of the Chair of the SC serves as the Headquarters
of the Network. The Chair of the SC can be any PI involved in the Network. The
Chair serves as the PI of the Headquarters and awards and implements the
scientific, operational, and organizational policies of the Network. The
headquarters provides the executive leadership, scientific direction, and
management for the Network. It serves as a center for information dissemination
to investigators and institutions in the Network as well as to others outside
the Network.
Funds: Funds will reside with 1) the individually funded U01 awardees in the
Network, and 2) the Headquarters.
The PI will have funds available through the individual U01 awards to support
the development of the scientific program and clinical protocols. All
investigators will be encouraged to seek supplemental funding through the Small
Business Innovation Award (SBIR, R43 and/or R44), Small Business Technology
Transfer (STTR, R41 and/or R42), Exploratory/Developmental grants (R21/R33),
and other research support mechanisms.
Core Funds for the Headquarters: Core Funds will be available to the Chair of
the SC. Applicants under this RFA should not apply for the Core Funds in their
U01 applications. Core Funds are reserved for post-award collaborative
research and for a variety of other functions:
1. Core Funds are used to expand participation within the Network through
supplemental funding to an investigator who is not part of the Network.
However, receipt of these supplemental funds does not, in and of itself, imply
membership in the Network or on the SC.
2. Core Funds are used for moving a new marker test to the point at which it
can be validated at multiple centers and in larger populations. Test reagents
will require scale-up at this point, and the SC will require sufficient funding
to contract to commercial laboratories or companies that can scale up
production and maintain quality of the reagents (i.e., monoclonal antibodies,
labels, etc.) and to Clinical Epidemiology and Validation Centers for subject
accrual. Core Funds will also be used for data management, travel, meetings,
and other collaborative activities of the Network.
Supplements from the Core Funds will provide direct costs and appropriate
facilities and administrative costs. The following example illustrates the
functions of the Network and the support it offers for moving basic research
findings into clinical practice:
An investigator within the Network identifies a putative biomarker through
original laboratory research. Based on the pilot research findings, the
putative marker seems to be useful for early cancer detection. The investigator
can then approach the SC for additional evaluation of the marker and possible
support for further testing. The SC then has the responsibility to review the
data on the potential marker using its standing formal criteria as a guide. The
SC can consult the Advisory Committee to obtain information on the requirements
and need for additional research on the marker. It also can consult the BRL and
the Clinical Centers regarding requirements for laboratory tests, needs for
quality assurance, and the availability of patient groups for clinical
validation. If necessary, scientific resources from other Centers can be pooled
to conduct studies. Concurrently, the informatics team in the DMCC can develop
tools for the analysis of results.
There is also flexibility so that investigators outside the Network can form
collaboration(s) with one of the existing centers, or directly bring their
discoveries to the SC (i.e., by Letter-of-Intent). To support such efforts, the
SC is able to use Core Funds to supplement the investigator’s ongoing research.
The investigator, in turn, must agree to share his research findings and become
part of the Network as an associate member.
Recipients of Core Funds, such as commercial laboratories or manufacturing
companies and institutions of outside investigators, participating for example
in validation studies, will be subjected to the resource sharing and
intellectual property requirements set forth in Section 3 of the Supplemental
Instructions of this RFA. Awardees must advise Core Funds recipients and
outside investigators of these requirements.
C. Objectives (applicable to Network as a Whole)
As described in the original RFA
(http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-98-028.html), the goals
of the Network are to discover, develop, and evaluate biomarkers/reagents
(Phases I-III) for the earlier detection of cancer and for the assessment of
risk for developing cancer. The intent of this RFA is to continue to foster
research investigations, technological innovations, and collaborations to
accelerate the development of biomarkers and tools that have the potential of
rapidly moving to Phase II and Phase III. Specifically, the objectives of
the Network include:
o the development and testing of promising biomarkers or technologies at
institutions with the necessary scientific and clinical expertise, to obtain
preliminary information to guide further testing;
o the timely and early phase evaluation of promising, analytically-validated
biomarkers or technologies, these evaluations would include measures of
diagnostic predictive accuracy, sensitivity, specificity, and, whenever
possible, medical benefits, such as predictors of clinical outcome or surrogate
endpoints for early detection and for prevention intervention clinical trials;
o the timely development of biomarker expression patterns, sometimes of
multiple markers simultaneously, which will serve as background information for
subsequent large definitive validation studies in the field of cancer detection
and screening;
o collaboration among academic and industrial leaders in molecular biology,
molecular genetics, proteomics, clinical oncology, computer science, public
health, and other areas to facilitate the development of high-throughput,
sensitive assay methods to identify biomarkers that are useful in detecting
cancer in its early stages and in assessing cancer risk;
o the conduct of the sequential early phases of clinical/ epidemiological
studies, (i.e., cross-sectional, retrospective; Phase I-III as described
above), to evaluate predictive value of biomarkers; and
o encouragement of collaboration and rapid dissemination of information among
awardees to ensure progress and avoid fragmentation of effort.
Because early detection and treatment issues are often related, the
Network seeks meaningful participation from various medical
organizations. In some of its activities, the Network may need to relate
programmatically to research infrastructures supported by NCI (e.g.,
Specialized Programs of Research Excellence
[SPOREs](http://spores.nci.nih.gov/), Cancer Genetics Network [CGN]
(http://epi.grants.cancer.gov/CGN/), Breast and Colon Cancer Family
Registries (http://epi.grants.cancer.gov/CCFR/index.html and
http://epi.grants.cancer.gov/BCFR/index.html),
Cooperative Human Tissue Network (http://www-chtn.ims.nci.nih.gov/),
Cancer Genome Anatomy Project (http://cgap.nci.nih.gov/),
with ongoing NCI clinical research programs/trials (e.g., Clinical Community
Oncology Program [CCOP](http://www3.cancer.gov/prevention/ccop/), Prostate,
Lung, Colon, and Ovarian Trial [PLCO])
(http://www3.cancer.gov/prevention/plco/index.html); or with other health
agencies, such as the Food and Drug Administration (FDA), the Department of
Defense (DOD), and the Veteran’s Administration (VA). Certain types of trials
in earlier detection, especially those involving treatment, may best be
conducted as inter-group studies with treatment-oriented cooperative groups,
such as the NCI Clinical Cooperative Groups, NCI designated Cancer Centers,
international collaborators, clinical epidemiologists, and health maintenance
organizations. The NCI anticipates that augmenting the EDRN expertise with a
broad base of clinical and public health perspectives will enable the Network
to apply existing methods and newly discovered technologies toward clinical
application.
D: Scope (applies to this RFA)
The scope of this RFA is to establish and enhance the BDL which form one of the
four scientific components within the Network. In the context of this RFA,
development will encompass correlative study to further develop and validate
biomarkers initially identified or characterized by applicants themselves or by
other investigators in accordance with the Phase I and Phase II of the
Biomarker Development Guidelines (Pepe et. al., 2001). The BDL will conduct
translational research in the biology of incipient neoplasia encompassing the
development, characterization and testing of biomarkers of early cancer or
risk, development of relevant technologies for biomarker detection, and
analytical tools for the evaluation of biomarkers. Translational research in
this context is defined as the movement of discoveries from the laboratories
into patient or population research settings or the movement of observations
from patient settings back to the laboratory. Major components of this process
are to standardize assays and to develop methods of analytic quality control.
The NCI has identified the following high-priority research opportunities in
early detection and risk assessment (for details see section ADVANCING
DISCOVERY AND ITS APPLICATION in the Plans and Priorities for Cancer Research
[http://plan.cancer.gov/]):
o Determine secreted proteins and other molecular signatures that correlate
with the presence of pre-cancerous and cancerous lesions;
o Develop highly sensitive and specific assays to detect cancer-related
proteins in body fluids;
o Develop highly specific and sensitive assays to detect tumor cells in body
fluids; and
o Develop highly specific and sensitive assays to detect molecular products of
tumor cells in body fluids with emphasis on the identification of molecular
determinants (risk factors) in accessible surrogate anatomic sites for the
less accessible major cancer sites
This RFA encourages the submission of applications in broad categories of
translational studies on complex cellular pathways, processes, and networks to
identify the molecular and cellular signatures of cells which can be used for
earlier detection or for risk assessment. Special emphasis should be placed on
cancers of common occurrence, such as prostate, breast, colon, lung, ovary,
upper-respiratory tract, pancreatic; and other less prevalent epithelial
cancers, which are the major causes of cancer-related mortality and have yet to
be controlled with screening and prevention.
These activities may include, but are not limited to:
I. Development of comprehensive panels of biomarkers/methods to identify
molecular changes, i.e., gene mutations, changes in gene and protein
expressions, and epigenetic changes associated with early stages of cancer.
o Identification and evaluation of molecular fingerprints/expression profiles
of genomic, proteomic, and epigenetic alterations in tissue and body fluids,
i.e., sputum, urine, pancreatic juices, serum, and plasma;
o Development of panels of biomarkers that can effectively identify early
disease phenotypes or pre-cancerous lesions involving abnormalities in many
biological processes;
o Determination of secreted proteins and protein profiles that correlate with
the presence of pre-cancerous and cancerous lesions;
o Identification and evaluation of molecular, genetic, and cytologic markers of
the risk of impending cancer; and
o Determination of membrane and membrane-associated proteins and profiles, and
other macromolecules that correlate with the presence of pre-cancerous and
cancerous lesions.
II. Identification and evaluation of molecular profiles for risk stratification
by improving pathological classification of early lesions. Expand marker
identification to predict early stages of disease and risk of recurrence.
o Development of molecular markers that can augment or replace tissue-based
assays.
o Development of markers/methods to improve current methods or modalities of
detection.
III. Development of highly specific and sensitive assays/biomarkers to detect
molecular alterations in circulating nucleic acids and cells in body fluids,
including serum and plasma.
o Development of reagents/biomarkers to detect cancer-specific signatures that
may signal the presence of small numbers of premalignant cells.
IV. Development of highly specific and sensitive markers to detect molecular
products of tumor cells in body fluids with emphasis on the identification of
molecular determinants in accessible surrogate anatomic sites for the less
accessible major cancer sites.
V. Study of molecular signatures to identify risk and early stage disease due
to infectious agents, pathogens, and other environmental agents.
Other approaches for the development of biomarkers for early detection of
cancer and identification of cancer risk will be accepted as well. However, the
application should clearly delineate the time-line for biomarkers development
from Phase I, to Phase II and to Phase III. Decision criteria should be
developed to triage biomarkers that are not relevant to identification of risk
and detection of cancer at earlier stages. The search for new markers should
reflect new information about key points in cancer biology (i.e., molecular
pathogenesis, apoptosis, cell cycle control). However, this RFA will not
support research of a fundamental nature, such as studies on growth regulation,
cell cycle control, or other basic studies that are not explicitly focused on
early detection and risk identification in humans. To expedite clinical
application, the validation of the biomarkers will be performed in
collaboration with the other scientific components of the Network.
For discovery of technology and molecular tools, applicants are encouraged to
develop collaboration with investigators participating in various NCI-sponsored
programs, such as the Innovative Molecular Analysis Technology (IMAT)
(http://otir.nci.nih.gov/tech/imat.html), and Unconventional Innovative Program
(UIP)(http://otir.nci.nih.gov/tech/uip.html). Some of the emerging
technologies, such as nanotechnology, could offer important new tools for
detection where existing and more conventional technologies may be reaching
their limits. Applications employing nanotechnology to provide direct readout
of genomic, proteomic, and epigenomic information both at the single cell and
single molecule level are encouraged. Applicants must advise any collaborating
SPOREs, IMAT, or UIP investigators that, with respect to these collaborations,
their institutions will be subject to the resource sharing and intellectual
property requirements set forth in Section 3 of the Supplemental Instructions
of this RFA.
MECHANISM OF SUPPORT
This RFA will use the NIH Cooperative Agreement (U01) award mechanism. As an
applicant, you will be primarily responsible for planning, directing, and
executing the proposed project. The anticipated award date is July 1, 2005.
Applications that are not funded in the competition described in this RFA may
be resubmitted as NEW investigator-initiated applications using the standard
receipt dates for NEW applications described in the instructions to the PHS 398
application. The RFA may be reissued in the future, contingent upon the
availability of funds.
This RFA uses just-in-time concepts. It also uses the non-modular budgeting
formats (see http://grants.nih.gov/grants/funding/modular/modular.htm). Follow
the instructions for non-modular budget research grant applications. This
program does not require cost sharing as defined in the current NIH Grants
Policy Statement at
http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part2.htm.
The NIH (U01) is a cooperative agreement award mechanism. In the cooperative
agreement mechanism, the Principal Investigator retains the primary
responsibility and dominant role for planning, directing, and executing the
proposed project, with NIH Program Coordinator being substantially involved as
a partner with the Principal Investigator, as described under the section
"Cooperative Agreement Terms and Conditions of Award.” At this time the NCI
anticipates that there will be a renewed competition after 5 years. If the NCI
does not continue the program, awardees may submit grant applications through
the usual investigator-initiated grants program. However, before submitting
such an application, applicants are advised to contact Program Coordinator
listed under the WHERE TO SEND INQUIRIES section listed below.
FUNDS AVAILABLE
The NCI intends to commit approximately $3 million in FY 2005 to fund five-six
new and/or competing continuation grants in response to this RFA. An applicant
may request a project period of up to 5 years. Because the nature and scope of
the proposed research will vary from application to application, it is
anticipated that the size and duration of each award will also vary. Although
the financial plans of the NCI provide support for this program, awards
pursuant to this RFA are contingent upon the availability of funds and the
receipt of a sufficient number of meritorious applications. At this time, the
NCI has not determined whether or how this solicitation will be continued
beyond the present RFA and related RFAs for the Network.
ELIGIBLE INSTITUTIONS
You may submit (an) application(s) if your institution has any of the following
characteristics:
o For-profit or non-profit organizations
o Public or private institutions, such as universities, colleges, hospitals,
and laboratories
o Units of State and local governments
o Eligible agencies of the Federal government
o Domestic or foreign institutions/organizations
o Faith-based or community-based organizations.
Domestic institutions may propose collaborations/consortia with foreign
institutions and vice versa.
For this RFA, teams composed of NIH intramural investigators may submit project
applications to become components of the Network, but they may not request or
receive funds from this program. The intramural applicant will not compete for
extramural funds
(http://deaintranet.nci.nih.gov/ncipolicy/final-intramural-pi.htm)
INDIVIDUALS ELIGIBLE TO BECOME PRINCIPAL INVESTIGATORS
Any individual with the skills, knowledge, and resources necessary to carry out
the proposed research is invited to work with his/her institution to develop an
application for support. Individuals from underrepresented racial and ethnic
groups as well as individuals with disabilities are always encouraged to apply
for NIH programs.
The NCI encourages applications from extramural and NIH intramural scientists
with broad expertise in the biology of cancer detection and risk assessment.
Researchers in NIH intramural laboratories may submit applications. However,
they may not receive salary, equipment, supplies, or other remuneration from
the extramural RFA set-aside funds for this program. An NIH intramural PI must
obtain the approval of her/his NIH Scientific Director, or a designated
official to allocate resources to the project, and must follow both the general
application format instructions and the additional guidelines for NIH
intramural project applications under "ADDITIONAL INSTRUCTIONS." NIH
intramural project applications will be reviewed and scored with the U01
applications. The NIH intramural projects selected by the NCI to be components
of the EDRN will participate in a manner that is analogous to the U01 awardees.
SPECIAL REQUIREMENTS
Definitions
Awardee: The institution to which a cooperative agreement (U01) is awarded.
Principal Investigator (PI): The investigator who is designated by the
applicant organization to direct the project to be supported by the U01 grant
or NIH intramural project in response to the RFA. The PI will assume the
responsibility and accountability to the applicant organization officials and
to the NCI for the performance and the proper conduct of the research supported
by the U01 mechanism or the NIH intramural project in accordance with the terms
and conditions that are stated in the RFA. The PI will be a voting member of
the SC.
NCI Program Director: A health scientist administrator from the NCI extramural
staff will provide normal stewardship for the U01 grants awardees.
NCI Program Coordinator: A health scientist administrator from the NCI
extramural staff, the Program Coordinator will be substantially involved in the
scientific coordination and collaboration within the Network, will have
responsibilities in broad scientific and programmatic issues, and will serve as
a voting member of the SC, as defined under the “Cooperative Agreement Terms
and Conditions of Award.”
Cooperative Agreement Terms and Conditions of Award
These special Terms of Award are in addition to and not in lieu of otherwise
applicable OMB administrative guidelines; DHHS Grant Administration Regulations
at 45 CFR Parts 74 and 92, and other; DHHS, PHS, and NIH Grant Administration
policy statements. (Part 92 applies when state and local governments are
eligible to apply as a "domestic organization.")
For NIH Intramural Projects, these terms and conditions will be provided to the
PI of the NIH Intramural Project and the NIH Institute Scientific Director at
the time of selection to be a Network component.
Under the cooperative agreement, the NCI purpose is to support and/or stimulate
the recipient's activity by involvement in and otherwise working jointly with
the award recipient in a partner role, but it is not to assume direction, prime
responsibility, or a dominant role in the activity. Consistent with this
concept, the dominant role and prime responsibility for the activity resides
with the awardee(s) for the project as a whole, although specific tasks and
activities in carrying out the studies will be shared among the awardees and
the NCI Program Coordinator.
A. Awardee Rights and Responsibilities: Extramural and NIH Intramural Projects
The PI of a U01 or NIH intramural project will have the primary authority and
responsibility to define objectives and approaches, including research design
and protocol development; participant recruitment and follow-up, if applicable,
data collection, quality control, interim data and safety monitoring, and to
plan, conduct, analyze, and publish results.
The PI of a U01 or NIH intramural project will assume responsibility for
managing individual protocols/research and collaborative projects approved by
the Steering Committee.
The PI of a U01 or NIH intramural project will assume responsibility and
accountability to the applicant organization officials and to the NCI for the
performance and proper conduct of the research supported by the U01 or the NIH
intramural project in accordance with the terms and conditions of the award.
The PI of a U01 or NIH intramural project will serve as a voting member of the
steering committee will attend the Planning meeting and two Steering Committee
meetings in the first year and two Steering Committee meetings per year and the
EDRN-Sponsored Gordon Conference every 18 months in subsequent years. The
attendance of PI at these meetings is considered an essential part of the
grant.
The PI of a U01 or NIH intramural project will be responsible for accepting and
implementing the goals, priorities, common protocols, procedures, and policies
agreed upon by the Steering Committee.
The PI of a U01 or NIH intramural project will retain custody of and have
primary rights to the data developed under these awards, subject to Government
rights of access consistent with current HHS, PHS, and NIH policies.
The PI of a U01 or NIH intramural project will be responsible for collaborating
on common research designs or protocols, including methods and requirements for
joint participation and collaboration as directed by the Steering Committee,
and handling of data, including appropriate sharing of methods and data among
collaborating organizations and submission of protocols to DMCC.
Network Collaborative Studies:
The PI of a U01 or NIH intramural project will be responsible for accepting and
implementing the goals, priorities, common protocols, procedures, and policies
agreed upon by the Steering Committee for the Network collaborative studies. In
some cases, the PI may be asked to serve as a lead investigator for the Network
collaborative studies.
The PI of a U01 or NIH intramural project will ensure Network and NCI review
and approval of protocol, concepts, final protocol documents, informed
consents, and study amendments, and advise NCI of changes in protocol status.
The PI of a U01 or NIH intramural project will be responsible for collaborating
on common research designs or protocols, including methods and requirements for
joint participation and collaboration as recommended by the Steering Committee,
and handling of data, including appropriate sharing of methods and data among
collaborating organizations.
The PI of a U01 or NIH intramural project will be responsible for accruing
subjects on collaborative studies approved by the Steering Committee.
B. NCI Extramural Staff Responsibilities
There will be only one NCI Program Coordinator for the Network. However, the
Program Coordinator may be assisted by other NCI Program Directors and Staff on
specific scientific issues as needed.
The NCI Program Coordinator will have substantial scientific programmatic
involvement during conduct of this activity, through technical assistance,
initiation of Network collaborative projects, data sharing and analysis,
composition of reports, and advice and coordination above and beyond normal
program stewardship for grants as described below.
Because of the Network’s diverse research agenda and the number of tasks that
have to be accomplished to achieve its goals, a number of NCI staff members may
interact with the Network as needed. The NCI Program Coordinator (a staff
member in the Division of Cancer Prevention) will assist the Network on
scientific and programmatic issues and well advise the Network on the
availability of other resources. A member from the Chemoprevention Branch,
NCI, will be available to assist the Network on intermediate endpoints and on
any ongoing chemoprevention trials relevant to the Network studies. A member
from the Biometry Branch, NCI, will be available to assist the Network on the
issues of study design, sample size, and other statistical computations. The
other NCI staff may assist and advise the Network on relevant programmatic and
scientific issues through the NCI Program Coordinator.
The Program Coordinator will convene the initial meeting of the SC, have voting
membership on the SC, and, as determined by that committee, its subcommittees.
Although the PI will have lead responsibilities in all collaborative tasks and
activities, it is anticipated that the NCI Program Coordinator will have lead
responsibilities in managing and sharing the broad programmatic issues among
awardees.
An NCI Program Director designated in the Notice of Grant Award will be
responsible for normal programmatic stewardship and monitoring of the awards.
The NCI Program Coordinator will identify other participating NCI staff. The
NCI Program Director may also serve as the NCI Program Coordinator.
The NCI reserves the right to adjust funding, withhold support, suspend,
terminate, or curtail the study or an individual award in the event of a
failure to comply with the Terms and Conditions of Award, substantial shortfall
in participant recruitment, follow-up, data reporting, quality control, or
other major breach of the protocol, or human subject ethical issues, whenever
applicable.
C. Collaborative Responsibilities
1. Steering Committee (SC): The SC will have major scientific management
oversight and responsibility for developing collaborative research designs,
protocols and manuals, facilitating the conduct and monitoring of studies, and
reporting study results. The SC will be composed of the PIs from each member
component (i.e., U01 or Intramural research project) of the Network, the
Principal Investigator of the DMCC, and the NCI Program Coordinator. Each
member component will have one vote. The Chair (non-NIH person) will be
selected by the Steering Committee. The institution of the Chair of the SC
will serve as the Headquarters (for definition, see Network Organization).
Subcommittees, including the existing ones, will be established/maintained by
the SC, as it deems appropriate; the NCI Program Coordinator will serve on
subcommittees as he/she deems appropriate.
After all the Network components have been funded, the SC will convene.
Responsibilities of the SC include, but are not limited to
o updating and refining established Network policies and procedures;
o updating and refining established policies and procedures for collaborative
projects, protocols, and Network-defined projects;
o updating and refining established policies and procedures for reviewing
changes in projects not showing translational significance at the request of
the laboratories/centers, and making recommendations to the NCI for replacing
the project with more promising ones with revised scope and adjusted budget
(increase in the budget will not be permitted);
o updating and refining established standards or “decision criteria” for
validating biomarkers/reagents for further clinical studies, such as testing
early detection strategies, or as risk factors; and
o updating and refining established policies and procedures for accepting,
reviewing, and recommending proposals from investigators outside the Network
for supplemental funding and expanding the Network participation;
Investigators are encouraged to review the EDRN Manual of Operation)
(http://www3.cancer.gov/prevention/cbrg/edrn/organization.html#manual)
2. The SC will establish Data and Safety Monitoring Committee (DSMC) for
clinical trials as appropriate to ensure protection of human subjects.
3. The SC will review patient accrual, follow-up, protocol compliance, results
of audits, and regulatory requirements at the participating Centers and
formally report the results of its reviews to the NCI.
4. The SC will promote and foster the inclusion of women and ethnic minorities
in clinical studies and assure the completeness of informed consent.
5. The Committee will track the Network research progress and assure that the
results of laboratory research and clinical studies are published in peer-
reviewed journals in a timely manner and in accordance with the publication
policies of the Network.
At any time during a Network project, the SC may ask BDLs or CEVCs to serve as
a BRL on an as needed basis. The SC may also examine the validation data for
biomarkers/reagents developed by the Network, and decide when a biomarker is
sufficiently validated, or recommend when to stop non-productive experiments
relating to biomarker validation.
6. The SC will discuss collaborative projects to be pursued jointly with the
funds set aside from the Headquarters and from individual U01 awardees, or NIH
intramural project budgets.
7. Collaborative studies/protocols will be approved by the Steering Committee.
Data will be submitted centrally to the DMCC. The SC will define the rules
regarding access to data and publications consistent with NCI policies.
8. The SC will plan one of several workshops during the Network project period
to inform the scientific community and relevant advocacy groups of the progress
made toward development and clinical application of biomarkers developed
through the Network. The NCI Program Coordinator, the Network Advisory
Committee, and other NCI staff will provide the SC with advice on participants
for the workshops and symposia. The Data Management and Coordinating Center
will manage the logistics for these meetings.
9. The Steering Committee or its Executive Committee in consultation with the
NCI will determine the PI of the Network-wide validation study.
Network Consulting Committee:
1. A Network Consulting Committee (NCC) was established by the NCI. The NCC
advises the SC through the NCI on relevant scientific issues, including study
design, prioritization of biomarker development, development of collaborative
study protocols, including decision criteria for clinical applications, i.e.,
early detection, prognosis, etc.
2. The membership to the Committee and duration of service was established by
the NCI in consultation with the Steering Committee. The membership includes
members/institutions not participating in the Network. The NCC includes basic
scientists, clinicians, prevention scientists, epidemiologists, ethicists,
statisticians, and members from relevant advocacy groups. Scientific experts
were drawn from various disciplines relevant to multi-center detection research
and experts in data management, biostatistics, and clinical study design.
3. The Chair of the NCC is elected by its members. The Chair of the SC also
serves as a member of the advisory committee. The NCI is represented by
relevant program staff.
4. The NCC evaluates the progress and success of the Network against the
criteria developed by the Steering Committee.
5. The NCC helps the NCI in site visits to the participating institutions, as
necessary.
6. The NCC collaborates with the SC to suggest participants for and to assist
in the implementation the workshops and symposia and to provide liaison between
the cancer research community and the Network.
Data Safety and Monitoring Committee:
The Data Safety and Monitoring Committee (DSMC) will be appointed by and report
to the Steering Committee in consultation with the EDRN Network Consulting
Committee and the Division Director. The DSMC will be composed of external,
non-participating scientists appointed by the Steering Committee to monitor
patient safety, conduct data audits, and document progress to the NCI Program
Director and the Advisory Committee. DSMC’s policy must be in compliance with
the NCI DSM policies at
http://cancer.gov/clinicaltrials/conducting/dsm-guidelines
D. Arbitration
A panel that is formed to review any scientific or programmatic disagreement
(within the scope of the U01 award or the NIH intramural project), between U01
awardees or NIH intramural projects and the NCI. The panel will be composed of
three members: one selected by the SC (with the NCI Program Coordinator not
voting), or by an individual U01 awardee or NIH intramural project in the event
of an individual disagreement; a second member selected by the NCI; and, the
third member selected by the two prior selected members. Any disagreement that
may arise on scientific/programmatic matters (within the scope of the award),
between award recipients and the NCI may be brought to arbitration.
This special arbitration procedure in no way affects the awardee's right to
appeal an adverse action that is otherwise appealable in accordance with the
PHS regulations at 42 CFR Part 50, Subpart D and DHHS regulation at 45 CFR Part
16.
WHERE TO SEND INQUIRIES
We encourage inquiries concerning this RFA and welcome the opportunity to
answer questions from potential applicants. Inquiries may fall into 4 areas:
scientific, technology, peer review, and financial or grants management issues:
o Direct your scientific questions for this RFA to:
Sudhir Srivastava, Ph.D., M.P.H.
Program Coordinator
Division of Cancer Prevention
National Cancer Institute
6130 Executive Boulevard, EPN Room 3142
Bethesda, MD 20892
Rockville, MD 20852 (for express/courier service)
Telephone: (301) 435-1594
FAX: (301) 402-8990
Email: srivasts@mail.nih.gov
o Direct questions about intellectual property, technology licensing, data
sharing, and research tools issues for this RFA to:
Wendy E. Patterson, Esq.
National Cancer Institute
Technology Transfer Branch
6120 Executive Boulevard, EPS Room 450
Bethesda, MD 20892-7182
Rockville, MD 20852 (for express/courier service)
Telephone: (301) 435-3110
FAX: (301) 402-2117
Email: wp23x@nih.gov
o Direct questions about peer review issues for this RFA to:
Referral Officer
National Cancer Institute
Division of Extramural Activities
6116 Executive Boulevard, Room 8041, MSC 8329
Bethesda, MD 20892-8329
Rockville, MD 20852 (for express/courier service)
Telephone: (301) 496-3428
FAX: (301) 402-0275
Email: ncirefof@dea.nci.nih.gov
o Direct questions about grants management matters for this RFA to:
Karen Chuang
Grants Administration Branch
National Cancer Institute
6120 Executive Boulevard, EPS Room 243
Bethesda, MD 20892
Rockville, MD 20852 (for express/courier service)
Telephone: (301) 496-2784
FAX: (301) 496-8601
Email: chuangk@mail.nih.gov
LETTER OF INTENT
Prospective applicants are asked to submit a letter-of-intent that includes the
following information:
o Descriptive title of the proposed research
o Name, address, and telephone number of the Principal Investigator
o Names of other key personnel
o Participating institutions
o Number and title of this RFA
Although a letter of intent is not required, is not binding, and does not enter
into the review of a subsequent application, the information that it contains
allows NCI staff to estimate the potential review workload and plan the review.
The letter of intent is to be sent by the date listed at the beginning of this
document. The letter-of-intent should be sent to:
Sudhir Srivastava, Ph.D., M.P.H.
Division of Cancer Prevention
National Cancer Institute
6130 Executive Boulevard, EPN Room 3142
Bethesda, MD 20892
Rockville, MD 20852 (for express/courier service)
Telephone: (301) 435-1594
FAX: (301)402-8990
Email: srivasts@mail.nih.gov
PRE-SUBMISSION MEETING
It is also the intent of the program to hold a pre-submission meeting on
November 3, 2004, in Bethesda, MD, with the potential applicants prior to the
letter of intent deadline.
SUBMITTING AN APPLICATION
Applications must be prepared using the PHS 398 research grant application
instructions and forms (rev. 5/2001). Applications must have a Dun and
Bradstreet (D&B) Data Universal Numbering System (DUNS) number as the Universal
Identifier when applying for Federal grants or cooperative agreements. The D&B
number can be obtained by calling (866) 705-5711 or through the web site at
http://www.dunandbradstreet.com/. The D&B number should be entered on line 11
of the face page of the PHS 398 form. The PHS 398 document is available at
http://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive
format. For further assistance, contact GrantsInfo, Telephone: (301) 435-0714;
Email: GrantsInfo@nih.gov.
SUPPLEMENTARY INSTRUCTIONS:
Special Instructions for Preparation of the Application
To promote the development of a collaborative program among the award
recipients, a number of issues need to be addressed in the application as
discussed below.
For U01 and NIH intramural applicants to this RFA, only the "Research Plan"
section of the PHS 398 grant application is changed. The remainder of the PHS
398 application form remains the same.
The "Research Plan", sections a to d are altered as follows. (The subsequent
sections e. to i. remain the same)
o The number of pages is increased from 25 to 35 pages; the 35-page limitation
applies to the replacement for sections a to d only, and does not include the
pages for sections e to i.
o The 35 pages should be apportioned as desired by the applicant to cover new
sections 1 to 3 that replace sections a to d. The three sections are: 1.
Applicant; 2. Scope of Research; and, 3. Collaborations.
Section 1 – Applicant. Applicants should briefly state the major
objectives of the project and describe what expertise the group encompasses, as
well as specialized or unique facilities, core resources, and services that are
available to support these objectives. In this section, applicants should
describe any ongoing grant-supported, institutional, or private sector
resources that augment or complement resources for which funding from this RFA
is sought. The roles of all key personnel, collaborators, and consultants who
are associated with the application may be briefly described; however, the full
extent of activities for each participant should be covered in Section 2.
Section 2 – Scope of Research. For competing renewal applicants, Section 2
should have a description of the goals of the previous grant and include the
scientific progress from the previous project period. Indicate the status of
developed markers according to the biomarker developmental phases (Pepe et.
al., 2001). For all applicants, depending on the composition and structure of
the group, this section may be organized as distinct projects or as one
integrated plan; in either case, the page limitation is the same. There is no
requirement for applicants to use the format of an R01 application. Instead,
applicants should define the major research questions and opportunities related
to objectives of EDRN that their group effort proposes to undertake.
Applicants should describe the approaches to be taken by the group in the
aggregate or as inter-dependent projects, and should describe the rationale for
approaches to be used or planned for development. Applicants are encouraged to
use this section of the application to highlight how the diverse expertise of
the group members contributes to the innovation of which the group is capable,
the flexibility they possess to redirect research when scientific progress
warrants it, and their ability to anticipate new directions, based on their
individual experience and ability to contribute to a collective effort. The
roles and expertise of all key personnel, collaborators, and consultants who
are associated with the application should be documented; letters from
collaborators and consultants should be included in Section 1 of the research
plan format as specified in the instructions for the Form PHS398 application.
Applicants should list and summarize each of the agreements with industry
collaborators, including a description of the materials, technologies and/or
expertise to be provided by such collaborators. Detailed documentation of
license agreement(s), intellectual property arrangements, and data sharing
concerning the proposed or existing collaboration with industrial partner(s)
will be requested as appropriate if an applicant is selected for consideration
for funding. These documents must be submitted by the Institutional Technology
Transfer Office.
Section 3 – Collaborations. For competing renewal applications, applicants
should describe their participation in the EDRN activities, and the
contributions in terms of collaborations within, and outside the Network in
meeting the EDRN missions (see EDRN Second Report,
http://www3.cancer.gov/prevention/cbrg/edrn/edrn_report2002.pdf, Metrics for
Programmatic Evaluation). For competing renewal, applicants are also required
to list all approved collaborative studies by the EDRN Executive Committee.
Letter of approval or the minutes of the EDRN Executive Committee indicating
the approval should included in Appendix.
For new applications, applicants should describe the experience of their group
in collaborative programs and activities with academic and industry partners.
Some examples of collaborations that may be provided in support of the
application are listed below:
o demonstrated evidence of collaborative projects and publications;
o demonstrated evidence of collaborative funding; and
o sharing of data and resources, e.g., specimens, technology, research
protocols.
The collaborative requirements are integral to EDRN activities and applications
will be judged for their scientific merits of the collaborative study, not just
the individual study. Applicants must highlight, whenever possible, the
collaborative component in the study with justifications as to why
collaboration is needed and how this would add value to their proposed study as
opposed to individual study? Applications should describe their plans for any
future collaborations for the proposed EDRN biomarker studies, both within and
outside Network. These plans could include other collaborative projects that
they are currently involved in, or plan to develop with any NCI-sponsored
programs, such as SPORE or Cooperative Groups.
o In Section 3, applicants must include their specific plans for responding to
the "Cooperative Agreement Terms and Conditions of Award" section. Applicants
should state their willingness to collaborate and share data freely with the
other EDRN components, to participate in planning and attending workshops and
symposia, to serve on the SC and be bound by its decisions, and to be able and
willing to share data and research resources with each other and the NCI.
Successful applicants will be expected to submit (on-line) information on
specimen collections per the Network’s Common Data Elements and register their
protocols with the Network’s DMCC.
o At the end of Section 3, applicants must append a letter from the applicant
institution describing how that institution intends to meet the NIH policies
for sharing of data or why data sharing is not possible. In this regard,
attention is drawn to the NIH Final Statement on Sharing Research Data
(http://grants.nih.gov/grants/policy/data_sharing/index.htm and
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html), which was
published in the NIH Guide on February 26, 2003. This is an extension of NIH
policy on sharing research resources, and reaffirms NIH support for the concept
of data sharing. The new policy becomes effective with the October 1, 2003
receipt date for applications or proposals to NIH. Investigators submitting an
NIH application will be required to include a plan for data sharing or to state
why data sharing is not possible.
o Applicants to this RFA must also include a research tools and resources
sharing plan in the letter to be appended to Section 3. Investigators
conducting biomedical research frequently develop unique research resources.
The policy of the NIH is to make available to the public the results and
accomplishments of the activities that it funds. NIH recognizes that certain
research activities may result in inventions and that grantees are entitled to
protect such inventions through patenting and licensing activities in
accordance with the Bayh-Dole Act, 35 USC § 200 et seq. and the implementing
regulations, 37 CFR Part 401 (“Bayh-Dole Act”). However, the EDRN’s core
mission of collaboration both between Network members and between Network
members and third party industry partners necessarily anticipates the sharing
of intellectual property arising out of research resources developed in
Network-related activities. To address the interest in assuring that research
resources are accessible, NIH requires applicants who respond to this RFA to
submit a plan (1) for sharing the unique research resources, e.g., human
biospecimens and novel cancer biomarkers, generated through the grant; and (2)
addressing how they will exercise intellectual property rights (described
below), should any be generated through this grant, while making such research
resources available to the broader scientific community.
The sharing of research resources and intellectual property plans must make
unique research resources readily available for research purposes to qualified
individuals within the scientific community in accordance with the NIH Grants
Policy Statement (http://grants.nih.gov/grants/policy/nihgps/) and the
Principles and Guidelines for Recipients of NIH Research Grants and Contracts
on Obtaining and Disseminating Biomedical Research Resources: Final Notice,
December 1999 (http://www.ott.nih.gov/policy/rt_guide_final.html and
http://ott.od.nih.gov/NewPages/64FR72090.pdf)(“NIH Research Tools Guidelines”).
These documents also define terms, parties, responsibilities, prescribe the
order of disposition of rights, prescribe a chronology of reporting
requirements, and delineate the basis for and extent of government actions to
retain rights. Patent rights clauses may be found at 37 CFR Part 401.14 and
are accessible from the Interagency Edison web page (http://www.iedison.gov);
see also, 35 USC § 210(c); Executive Order 12591, 52 FR 13414 (Apr. 10, 1987);
and Memorandum on Government Patent Policy (Feb. 18, 1983). If applicant
investigators plan to collaborate with third parties, the research tools
sharing plan must explain how such collaborations will not restrict their
ability to share research materials produced with NIH funding. NCI believes
that applicants can satisfy the requirement to submit the research resources
plan and intellectual property plan in a number of ways.
GUIDANCE FOR PREPARATION OF RESEARCH RESOURCES PLAN AND INTELLECTUAL PROPERTY
PLAN
The EDRN is premised on the belief that an established integrated, multi-
disciplinary environment will expedite clinical applications of biomarker
research. Comprised of 31 principal members, the EDRN is organized in four
components: 18 BDLs, three BVLs, nine CEVCs, and one DMCC. From the outset,
the NCI anticipated that EDRN members would collaborate with industry both to
develop biomarkers and/or reagents and to provide a clinical environment for
the evaluation of new technologies. Early interactions with industry are
expected to permit research collaborations likely to benefit both EDRN grantees
and industry partners. It is hoped that validated biomarkers may ultimately be
commercialized into diagnostic products for early detection of cancer and
cancer risk. Many of the EDRN investigators have had active collaborations
with industry. While the one university/one company collaborations have worked
well, there is general agreement that successful multi-institution/company
collaborations have been harder to implement.
Restricted availability of unique research resources, upon which further
studies are dependent, can impede the advancement of research. The NIH is
interested in ensuring that the research resources developed through this grant
also become readily available to the broader research community in a timely
manner for further research, development, and application, in the expectation
that this will lead to products and knowledge of benefit to the public health.
Investigators conducting biomedical research frequently develop unique research
resources. The policy of the NIH is to make available to the public the results
and accomplishments of the activities that it funds. To address this interest
in assuring research resources are accessible, NIH requires applicants who
respond to this RFA to submit a plan: (1) for sharing the research resources
generated through the grant (e.g., human biospecimens and novel cancer
biomarkers); and (2) addressing how they will exercise intellectual property
rights, should any be generated through this grant, while making such research
resources available to the broader scientific community consistent with this
initiative. Therefore, the research resources tools sharing plan and
intellectual property management plans must make unique research resources
readily available for research purposes to qualified individuals within the
scientific community in accordance with the NIH Grants Policy Statement
(http://grants.nih.gov/grants/policy/nihgps/) and the Principles and Guidelines
for Recipients of NIH Research Grants and Contracts on Obtaining and
Disseminating Biomedical Research Resources: Final Notice, December 1999
(http://www.ott.nih.gov/policy/rt_guide_final.html and
http://ott.od.nih.gov/NewPages/64FR72090.pdf)(“NIH Research Tools Policy”).
These documents also: (1) define terms, parties, and responsibilities; (2)
prescribe the order of disposition of rights and a chronology of reporting
requirements: and (3) delineate the basis for and extent of government actions
to retain rights. Patent rights clauses may be found at 37 CFR Part 401.14 and
are accessible from the Interagency Edison web page, (http://www.iedison.gov);
see also, 35 USC § 210(c); Executive Order 12591, 52 FR 13414 (Apr. 10, 1987);
and Memorandum on Government Patent Policy (Feb. 18, 1983). If applicant
investigators plan to collaborate with third parties, the research tools
sharing plan must address how such collaborations will not restrict their
ability to share research materials produced with NIH funding. NCI believes
that applicants can satisfy the requirement to submit the research resources
plan and intellectual property plan in a number of ways.
Reviewers will comment, as appropriate, on the adequacy and feasibility of the
sharing of research resources plan and the intellectual property plan.
Comments on the plans and any concerns will be presented in an administrative
note in the Summary Statement. These comments will not affect the priority
score of the proposal. NIH program staff will consider the adequacy of the
plans in determining whether to recommend an application for award. The
approved plans will become a condition of the grant award and Progress Reports
must contain information on activities for the sharing of research resources
and intellectual property.
Where it is anticipated that there will be an exchange of collections of human
tissues, consideration should also be given to obtaining the appropriate
assurances from the DHHS Office of Human Subject Protections
(http://www.hhs.gov/ohrp/assurances/assurances_index.html)
and necessary IRB approvals and/or exemptions. In addition, issues pertaining
to the protection of patient identifiable information under the Privacy Rule
of the Health Insurance Portability and Accountability Act of 1976 (HIPAA)
should be addressed. For more information concerning the HIPAA Privacy Rule, see
(http://www.hhs.gov/ocr/hipaa).
In the development of the research resource sharing and intellectual property
management plans, applicants should confer with their institutions’ office(s)
responsible for handling technology transfer related matters and/or sponsored
research. If applicants or their representatives require additional guidance
in preparing these plans, they are encouraged to make further inquiries to the
appropriate contacts listed above for such matters. Further, applicants may
wish to independently research and review examples of approaches considered by
other institutions such as those described on the NCI Technology Transfer
Branch website (http://ttc.nci.nih.gov/intellectualproperty/).
Budget:
NOTE: NIH intramural project should supply the budget information and a
composite budget as described below in “ADDITIONAL INSTRUCTIONS FOR NIH
INTRAMURAL PROJECT APPLICANTS” for NIH Intramural Project Applicants.
1. Applicants must budget for travel and per diem expenses for SC meetings. In
the first year, applicants should plan for two investigators, the principal
investigator and an additional senior investigator, to attend a Planning
Meeting and two SC meetings. In the second and subsequent years, applicants
should plan for the PI and another investigator to attend two SC meetings per
year.
2. Applicants must budget for travel and per diem expenses for participation in
Network workshops and symposia. Applicants should plan that at least two
investigators will attend a workshop or symposium every year.
3. Applicants must set aside 20 percent of their annual budgets or the actual
amount of funds that was approved by the program staff for validation or any
collaborative studies (applies to competing renewal applicant who is
participating on ongoing validation studies) as follows:
o The competing renewal applicant should set aside funds from the first year
onward; and
o The new applicant should set aside funds after the first year onward for
Network collaborative studies.
The use of these set-aside funds will be restricted and must be reviewed and
approved by the Steering Committee and then recommended to, and approved by the
NCI for release from the individual U01 awards. Indicate this amount in the
Other Expenses category under the heading “Network Collaborative Funds.”
4. Applicants must budget for data collection on relevant common data elements
(CDEs) for specimens during the course of study. For CDEs, please visit the
EDRN web site http://www.cancer.gov/edrn.
ADDITIONAL INSTRUCTIONS FOR NIH INTRAMURAL PROJECT APPLICANTS: NIH intramural
project applicants must use the PHS 398 application form and the modified
format and content described above with the following additional modifications.
o On the Face Page, fill out only items 1., 2., 3. (leave item 3c. blank), 4.,
and 5. The remainder of the items should be left blank, AND THE APPLICATION
MUST NOT BE SIGNED BY EITHER THE PI OR AN NIH INSTITUTE OFFICIAL.
o Do not submit "Other Support," Checklist," "Personnel Report," or "Personal
Data" pages.
o The PI must obtain the approval of her/his NIH Institute Scientific Director
for applying, for collaboration, for participating as a component of the EDRN
under the terms and conditions of the RFA, and for complying with the policies
of the Steering Committee. A copy of that letter of approval must be provided
as part of a cover letter, addressed to the NCI Referral Officer, for the
application.
o The budget pages should supply the time and effort for each project
participant, but no other budget figures should be included. The resources
available for the project and the research environment should be carefully
described, but no budget figures should be included. The NIH Institute
Scientific Director, as part of the letter of approval for participation, must
verify that appropriate intramural resources will be allocated to the project
described in the application if it merits funding, and provide assurance that
the conduct of the project will comply with the PHS regulations for research
involving human subjects (if applicable), with the PHS policy on vertebrate
animal research, and with the PHS policies for data sharing and access to
research tools.
USING THE RFA LABEL: The RFA label available in the PHS 398 (rev. 5/2001)
application form must be affixed to the bottom of the face page of the
application. Type the RFA number, CA-05-023 on the label. Failure to use this
label could result in delayed processing of the application such that it may
not reach the review committee in time for review. In addition, the RFA title,
THE EARLY DETECTION RESEARCH NETWORK: BIOMARKER DEVELOPMENTAL LABORATORIES, and
number, RFA CA-05-023, must be typed on line 2 of the face page of the
application form and the YES box must be marked. The RFA label is also
available at http://grants.nih.gov/grants/funding/phs398/labels.pdf.
SENDING AN APPLICATION TO THE NIH: For U01 applicants only (NIH intramural
applicants must use the address in the Section below entitled "FOR NIH
INTRAMURAL APPLICANTS"), submit a signed, typewritten original of the
application, including the Checklist, and three signed photocopies, in one
package to:
Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710
Bethesda, MD 20817 (for express/courier service)
At the time of submission, two additional copies of the application and all
five copies of the appendix material must be sent to:
Referral Officer
Division of Extramural Activities
National Cancer Institute
6116 Executive Blvd., Room 8041, MSC-8329
Rockville, MD 20852 (express courier)
Bethesda MD 20892-8329
Telephone: (301) 496-3428 (for express/courier service)
For NIH intramural Applicants:
o Submit an unsigned, typewritten original of the application, and five
photocopies to:
Referral Officer
Division of Extramural Activities
National Cancer Institute
6116 Executive Blvd., Room 8041, MSC-8329
Rockville, MD 20852 (express courier)
Bethesda MD 20892-8329
DO NOT send the application or any copies to the Center for Scientific Review.
NIH intramural project applications must also be received by December 20, 2004.
If an application is received after that date, it will be returned to the
applicant without review.
Appendices should be comprised of single-sided, unbound materials.
APPLICATIONS HAND-DELIVERED BY INDIVIDUALS TO THE NATIONAL CANCER INSTITUTE
WILL NO LONGER BE ACCEPTED. This policy does not apply to courier deliveries
(i.e., FEDEX, UPS, DHL, etc.)
(http://grants.nih.gov/grants/guide/notice-files/NOT-CA-02-002.html). This policy
is similar to and consistent with the policy for applications addressed to Centers
for Scientific Review as published in the NIH Guide Notice at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-012.html.
APPLICATION PROCESSING: Applications must be received on or before the
application receipt date, December 20, 2004, listed in the heading of this RFA.
If an application is received after that date it will be returned to the
applicant without review.
Although there is no immediate acknowledgement of the receipt of an
application, applicants are generally notified of the review and funding
assignment within 8 weeks.
The Center for Scientific Review (CSR) will not accept any application in
response to this RFA that is essentially the same as one currently pending
initial review, unless the applicant withdraws the pending application.
However, when a previously unfunded application, originally submitted as an
investigator-initiated application, is to be submitted in response to an RFA,
it is to be prepared as a NEW application. That is, the application for the
RFA must not include an Introduction describing the changes and improvements
made, and the text must not be marked to indicate the changes from the previous
unfunded version of the application. Please note that amended applications will
be accepted from the previous issuance of this RFA, CA-04-006, and responses to
the reviewers critiques will be included.
PEER REVIEW PROCESS
Upon receipt, U01 applications will be reviewed for completeness by the CSR and
for responsiveness by NCI program staff. NIH intramural project applications
will be reviewed for completeness by the NCI Division of Extramural Activities,
and for responsiveness by NCI program staff. Incomplete and/or non-responsive
applications will not be reviewed.
U01 and NIH intramural project applications that are complete and responsive to
the RFA will be evaluated for scientific and technical merit by an appropriate
peer review group convened by the Division of Extramural Activities at the NCI
in accordance with the review criteria stated below. As part of the initial
merit review, all applications will:
o Undergo a process in which only those applications deemed to have the highest
scientific merit, generally the top half of the applications under review, will
be discussed and assigned a priority score
o Receive a written critique
o Receive a second level review by the National Cancer Advisory Board.
REVIEW CRITERIA
The goals of NIH-supported research are to advance our understanding of
biological systems, improve the control of disease, and enhance health. In the
written comments, reviewers will be asked to evaluate the application in order
to judge the likelihood that the proposed research will have a substantial
impact on the pursuit of these goals. The scientific review group will address
and consider each of these criteria in assigning the application’s overall
score, weighting them as appropriate for each application.
o Significance
o Approach
o Innovation
o Investigator
o Environment
The application does not need to be strong in all categories to be judged
likely to have major scientific impact and thus deserve a high priority score.
For example, an investigator may propose to carry out important work that by
its nature is not innovative but is essential to move a field forward.
1. Significance:
o Does the proposed research convey the urgency of scientific needs in the area
of biomarker-based diagnostics possible only through a consortium or a network
approach?
o Does the proposal uniquely discuss challenges and issues relevant to cancer
detection and screening?
o How would the proposed research complement or augment existing detection
systems or methodologies?
o What is the immediacy of the research opportunity in light of the EDRN-
established phases of biomarker development for early detection of cancer and
potentials for moving biomarkers to Phase II or Phase III in the next five
years. (See “Research Objective: Background”).
o To what extent are the specific aims integrated to address the proposed
goals?
o What is the potential impact of these studies, if successful?
2. Approach:
o Are the conceptual framework, design, methods, and analyses adequately
developed and appropriate to the aims of the project?
o Has the applicant clearly defined their objective, hypothesis and scientific
plan?
o Does the applicant acknowledge potential problem areas and consider
alternative tactics?
o Can these approaches be used to derive biomarkers/reagents for a variety of
malignant tumors?
o Are the parameters, such as sensitivity, specificity, predictive value chosen
to characterize the biomarkers/reagents sufficient and appropriate?
o Are the study designs supported by adequate sample size and statistical
reasoning?
o Are the considerations given to minimize biases and reproducibility issues o
in the proposed study design?
o Are the criteria chosen to characterize biomarkers/reagents for early
detection and/or risk assessment appropriate and adequate in light of the EDRN-
established phases of biomarker development for early detection of cancer (See
“Research Objective: Background”)?
o Does the applicant have demonstratable evidence for bringing biomarkers to
Phase II or Phase III?
o Is the proposed approach or technology adaptable, or has the potential to
analyze large samples in population setting for screening purposes?
3.Innovation:
o Is the project original and innovative?
o Does the project challenge existing paradigms or clinical practice?
o Does the project develop or employ novel concepts, approaches, methodologies,
tools, or technologies for this area?
o Will the approaches advance the field of biomarkers/reagents development in
the context of cancer detection and risk assessment?
4. Investigators:
o Are the principal investigator and collaborators appropriately trained and
well suited to carry out this work?
o Does the principal investigator have a track record of publishing papers
relevant to cancer detection and risk identification?
o Are the key personnel identified in the proposal experienced in cancer
detection and prevention research?
o To what extent do these investigators have the necessary complementary
skills?
o Have collaborations been established or consultants identified to provide the
appropriate depth and breadth of scientific expertise required for the project?
o Will this team of investigators contribute unique skills to the overall
Network?
5. Environment:
o Does the applicant have access to required human specimens, e.g. tissues,
biological fluids, archived materials?
o Does the applicant have access to pathology review and documentation of
pathology report?
o Does the applicant have the cooperation of surgeons and pathologists?
o Does the applicant have access to normal tissues from the patients, and
access to matched controlled specimens?
o Are the facilities for experimentation appropriate to support the endeavor?
o Does the scientific environment in which the work will be done contribute to
the probability of success?
o Do the proposed experiments take advantage of unique features of the
institutional scientific environment and incorporate the best use of
collaborative arrangements?
o Is there evidence of institutional support?
o Is there institutional support for computer services, including Internet
access?
o Has the applicant adequately addressed his/her institutional patent policy?
ADDITIONAL REVIEW CRITERIA: In addition to the above criteria, the following
items will be considered in the determination of scientific merit and the
priority score:
1. Collaborative Strengths.
o Are plans for collaborations provided for individual research objectives?
o To what extent are these collaborations necessary for the successful
completion of the research plan?
o Are there adequate plans for effective interaction and coordination with the
Network components, the SC, the DMCC and the NCI?
o Do the investigators state their willingness to collaborate and share
information?
o Do the investigators state their willingness to abide by the priorities and
policies agreed upon by the SC for collaborative studies?
o Have the applicants proposed sound strategies for communication among
themselves, with the other Network components, and with the NCI?
2. Budget. For U01 applications, does the apportionment of the budget for
biomarkers development, characterization, and/or technology innovation indicate
that the applicants understand the requirements of managing a Biomarker
Developmental Laboratory in the Network enterprise? For the NIH intramural
project applications, is the commitment of effort appropriate to the scope of
the project, and are the resources and environment adequate to support the
project?
PROTECTION OF HUMAN SUBJECTS FROM RESEARCH RISK: The involvement of human
subjects and protections from research risk relating to their participation in
the proposed research will be assessed. (See criteria included in the section
on Federal Citations, below.) Describe accrual and collection of specimens
available for each disease site that will be used in the study in compliance
with HIPPA.
INCLUSION OF WOMEN, MINORITIES AND CHILDREN IN RESEARCH: The adequacy of plans
to include subjects from both genders, all racial and ethnic groups (and
subgroups), and children as appropriate for the scientific goals of the
research. Plans for the recruitment and retention of subjects will also be
evaluated. (See Inclusion Criteria in the sections on Federal Citations,
below.)
CARE AND USE OF VERTEBRATE ANIMALS IN RESEARCH: If vertebrate animals are to be
used in the project, the five items described under Section f of the PHS 398
research grant application instructions (rev. 5/2001) will be assessed.
ADDITIONAL REVIEW CONSIDERATIONS
Sharing Research Data
Applicants requesting $500,000 or more in direct costs in any year of the
proposed research must include a data sharing plan in their application. The
reasonableness of the data sharing plan or the rationale for not sharing
research data will be assessed by the reviewers. However, reviewers will not
factor the proposed data sharing plan into the determination of scientific
merit or priority score. (See Federal Citations, below.)
BUDGET: The reasonableness of the proposed budget and the requested period of
support in relation to the proposed research.
RECEIPT AND REVIEW SCHEDULE
Letter of Intent Receipt Date: November 22, 2004
Application Receipt Date: December 20, 2004
Peer Review Date: March 2005
Council Review: June 2005
Earliest Anticipated Start Date: July 1, 2005
AWARD CRITERIA
Award criteria that will be used to make award decisions include:
o Scientific merit (as determined by peer review);
o Availability of funds; and
o Programmatic priorities.
REQUIRED FEDERAL CITATIONS
ANIMAL WELFARE PROTECTION: Recipients of PHS support for activities involving
live, vertebrate animals must comply with PHS Policy on Humane Care and Use of
Laboratory Animals
(http://grants.nih.gov/grants/olaw/references/PHSPolicyLabAnimals.pdf), as
mandated by the Health Research Extension Act of 1985
(http://grants.nih.gov/grants/olaw/references/hrea1985.htm), and the USDA
Animal Welfare Regulations
(http://www.nal.usda.gov/awic/legislat/usdaleg1.htm), as applicable.
HUMAN SUBJECTS PROTECTION: Federal regulations (45CFR46) require that
applications and proposals involving human subjects must be evaluated with
reference to the risks to the subjects, the adequacy of protection against
these risks, the potential benefits of the research to the subjects and others,
and the importance of the knowledge gained or to be gained. See
http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm
DATA AND SAFETY MONITORING PLAN: Data and safety monitoring is required for all
types of clinical trials, including physiologic, toxicity, and dose-finding
studies (phase I); efficacy studies (phase II); efficacy, effectiveness and
comparative trials (phase III). The establishment of data and safety
monitoring boards (DSMBs) is required for multi-site clinical trials involving
interventions that entail potential risk to the participants. Research
components involving Phase I and II clinical trials must include provisions for
assessment of patient eligibility and status, rigorous data management, quality
assurance, and auditing procedures. In addition, it is NIH policy that all
clinical trials require data and safety monitoring, with the method and degree
of monitoring being commensurate with the risks (See NIH Policy for Data and
Safety Monitoring, NIH Guide for Grants and Contracts, June 12, 1998, at
http://grants.nih.gov/grants/guide/notice-files/not98-084.html.)
Clinical trials supported or performed by NCI require special considerations.
The method and degree of monitoring should be commensurate with the degree of
risk involved in participation and the size and complexity of the clinical
trial. Monitoring exists on a continuum from monitoring by the principal
investigator/project manager or NCI program staff or a Data and Safety
Monitoring Board (DSMB). These monitoring activities are distinct from the
requirement for study review and approval by an Institutional review Board
(IRB). For details about the Policy for the NCI for Data and Safety Monitoring
of Clinical trials, see
http://deainfo.nci.nih.gov/grantspolicies/datasafety.htm. For Phase I and II
clinical trials, investigators must submit a general description of the data
and safety monitoring plan as part of the research application. For additional
information, see NIH Guide Notice on “Further Guidance on a Data and Safety
Monitoring for Phase I and II Trials” at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-038.html.
Information concerning essential elements of data safety monitoring plans for
clinical trials funded by the NCI is available at
http://www.cancer.gov/clinical_trials/.
SHARING RESEARCH DATA: Investigators submitting an NIH application seeking more
than $500,000 or more in direct costs in any single year are expected to
include a plan for data sharing
(http://grants.nih.gov/grants/policy/data_sharing) or state why this is not
possible. Investigators should seek guidance from their institutions, on
issues related to institutional policies, local IRB rules, as well as local,
state and Federal laws and regulations, including the Privacy Rule. Reviewers
will consider the data sharing plan but will not factor the plan into the
determination of the scientific merit or the priority score.
INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH: It is the policy of the
NIH that women and members of minority groups and their sub-populations must be
included in all NIH-supported clinical research projects unless a clear and
compelling justification is provided indicating that inclusion is inappropriate
with respect to the health of the subjects or the purpose of the research. This
policy results from the NIH Revitalization Act of 1993 (Section 492B of Public
Law 103-43).
All investigators proposing clinical research should read the "NIH Guidelines
for Inclusion of Women and Minorities as Subjects in Clinical Research -
Amended, October, 2001," published in the NIH Guide for Grants and Contracts on
October 9, 2001
(http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-001.html);
a complete copy of the updated Guidelines are available at
http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm.
The amended policy incorporates: the use of an NIH definition of clinical
research; updated racial and ethnic categories in compliance with the new OMB
standards; clarification of language governing NIH-defined Phase III clinical
trials consistent with the new PHS Form 398; and updated roles and
responsibilities of NIH staff and the extramural community. The policy
continues to require for all NIH-defined Phase III clinical trials that: (a)
all applications or proposals and/or protocols must provide a description of
plans to conduct analyses, as appropriate, to address differences by sex/gender
and/or racial/ethnic groups, including subgroups if applicable; and (b)
investigators must report annual accrual and progress in conducting analyses,
as appropriate, by sex/gender and/or racial/ethnic group differences.
INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS: The
NIH maintains a policy that children (i.e., individuals under the age of 21)
must be included in all human subjects research, conducted or supported by the
NIH, unless there are scientific and ethical reasons not to include them.
All investigators proposing research involving human subjects should read the
"NIH Policy and Guidelines" on the inclusion of children as participants in
research involving human subjects that is available at
http://grants.nih.gov/grants/funding/children/children.htm.
REQUIRED EDUCATION ON THE PROTECTION OF HUMAN SUBJECT PARTICIPANTS: NIH policy
requires education on the protection of human subject participants for all
investigators submitting NIH proposals for research involving human subjects.
You will find this policy announcement in the NIH Guide for Grants and
Contracts Announcement, dated June 5, 2000, at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html. A
continuing education program in the protection of human participants in
research is available online at: http://cme.nci.nih.gov/.
HUMAN EMBRYONIC STEM CELLS (hESC): Criteria for federal funding of research on
hESCs can be found at http://stemcells.nih.gov/index.asp
http://stemcells.nih.gov/index.asp and at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html. Only
research using hESC lines that are registered in the NIH Human Embryonic Stem
Cell Registry will be eligible for Federal funding (see http://escr.nih.gov).
It is the responsibility of the applicant to provide, in the project
description and elsewhere in the application as appropriate, the official NIH
identifier(s) for the hESC line(s) to be used in the proposed research.
Applications that do not provide this information will be returned without
review.
PUBLIC ACCESS TO RESEARCH DATA THROUGH THE FREEDOM OF INFORMATION ACT: The
Office of Management and Budget (OMB) Circular A-110 has been revised to
provide public access to research data through the Freedom of Information Act
(FOIA) under some circumstances. Data that are (1) first produced in a project
that is supported in whole or in part with Federal funds and (2) cited publicly
and officially by a Federal agency in support of an action that has the force
and effect of law (i.e., a regulation) may be accessed through FOIA. It is
important for applicants to understand the basic scope of this amendment. NIH
has provided guidance at
http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm.
Applicants may wish to place data collected under this RFA in a public archive,
which can provide protections for the data and manage the distribution for an
indefinite period of time. If so, the application should include a description
of the archiving plan in the study design and include information about this in
the budget justification section of the application. In addition, applicants
should think about how to structure informed consent statements and other human
subjects procedures given the potential for wider use of data collected under
this award.
STANDARDS FOR PRIVACY OF INDIVIDUALLY IDENTIFIABLE HEALTH INFORMATION: The
Department of Health and Human Services (DHHS) issued final modification to the
“Standards for Privacy of Individually Identifiable Health Information,” the
“Privacy Rule,” on August 14, 2002. The Privacy Rule is a federal regulation
under the Health Insurance Portability and Accountability Act (HIPAA) of 1996
that governs the protection of individually identifiable health information,
and is administered and enforced by the DHHS Office for Civil Rights (OCR).
Decisions about applicability and implementation of the Privacy Rule reside
with the researcher and his/her institution. The OCR website
(http://www.hhs.gov/ocr/) provides information on the Privacy Rule, including a
complete Regulation Text and a set of decision tools on “Am I a covered
entity?” Information on the impact of the HIPAA Privacy Rule on NIH processes
involving the review, funding, and progress monitoring of grants, cooperative
agreements, and research contracts can be found at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html.
URLs IN NIH GRANT APPLICATIONS OR APPENDICES: All applications and proposals
for NIH funding must be self-contained within specified page limitations.
Unless otherwise specified in an NIH solicitation, Internet addresses (URLs)
should not be used to provide information necessary to the review because
reviewers are under no obligation to view the Internet sites. Furthermore, we
caution reviewers that their anonymity may be compromised when they directly
access an Internet site.
HEALTHY PEOPLE 2010: The Public Health Service (PHS) is committed to achieving
the health promotion and disease prevention objectives of "Healthy People
2010," a PHS-led national activity for setting priority areas. This RFA is
related to one or more of the priority areas. Potential applicants may obtain a
copy of "Healthy People 2010" at http://www.health.gov/healthypeople.
AUTHORITY AND REGULATIONS: This program is described in the Catalog of Federal
Domestic Assistance at http://www.cfda.gov/ and is not subject to the
intergovernmental review requirements of Executive Order 12372 or Health
Systems Agency review. Awards are made under the authorization of Sections 301
and 405 of the Public Health Service Act as amended (42 USC 241 and 284)(cite
appropriate authorizations) and under Federal Regulations 42 CFR 52 and 45 CFR
Parts 74 and 92 (cite relevant regulations). All awards are subject to the
terms and conditions, cost principles, and other considerations described in
the NIH Grants Policy Statement. The NIH Grants Policy Statement can be found
at http://grants.nih.gov/grants/policy/policy.htm (Also cite other relevant
policies.)
The PHS strongly encourages all grant recipients to provide a smoke-free
workplace and discourage the use of all tobacco products. In addition, Public
Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain
facilities (or in some cases, any portion of a facility) in which regular or
routine education, library, day care, health care, or early childhood
development services are provided to children. This is consistent with the PHS
mission to protect and advance the physical and mental health of the American
people.
References
Early Detection Research Network. Disease Markers. Volume 15, No. 4, December
1999, pages 213-219.
Pepe, M.S., Etzioni, R., Feng, Z., Potter, J., Thompson, M. L., Thornquist, M.,
Yasui, Y. (2001). Phases of biomarker development for early detection of
cancer. J Natl Cancer Inst. 93, 1054-1061.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
|
Department of Health and Human Services |
|
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |